Medtronic has announced the launch of the Avalus Ultra surgical aortic tissue valve.
The valve is designed to facilitate ease of use at implant and lifetime patient management, the company said in a press release.
“Patients with aortic stenosis are experiencing more complex disease, and therefore, procedures need to evolve to optimise their surgical care,” said Pieter Kappetein, vice president and chief medical officer of the Cardiac Surgery, Structural Heart, and Mechanical Circulatory Support businesses in the Medtronic Cardiovascular portfolio. “Rooted in this evolving need, surgeons are demanding innovative technologies like the Avalus Ultra valve that is designed for increased ease of use and long-term durability to serve patients over their lifetime.”
“Cardiac surgeons are looking to industry to partner with them to deliver improved innovation to treat their patients efficiently and effectively,” said Karim Bandali, president of the Cardiac Surgery business in the Medtronic Cardiovascular portfolio. “The Avalus Ultra valve builds on several successful innovation launches this year, including the acquisition and launch of the Penditure LAA [left atrial appendage] exclusion system. Aligned our mission, Medtronic is committed to making the investments needed to advance and deliver innovative, lifesaving devices for better lifetime patient management.”
The Avalus Ultra valve received FDA approval in January 2024 and is currently only commercially available in the USA.
